[IBS 코로나19 리포트 시즌2] How far have you come to develop an antibody treatment for COVID-19: Dong-A Science
Celltrion chairman’s remarks “contemplating the development of a vaccine for Corona 19,” the share price is 2%
Supplied the first domestic antibody treatment drug’Rekironaju’ to medical institutions in the middle of this month-Cheonji Ilbo
[비즈헬스] Celltrion’s corona 19 treatment’Rekironaju’ approval is imminent… Opinion that approval is possible under the premise of Phase 3
Ministry of Food and Drug Safety’s Central Pharmaceutical Affairs Commission “Recommendation for use of celltrion antibody therapy for moderate and high-risk patients with mild symptoms”: Dong-A Science
[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓
![[IBS 코로나19 리포트 시즌2] How far have you come to develop an antibody treatment for COVID-19: Dong-A Science](http://image.dongascience.com/Photo/2021/02/2b221aa699701acb841498e4451794a8.jpg "[IBS 코로나19 리포트 시즌2] How far have you come to develop an antibody treatment for COVID-19: Dong-A Science")
![[비즈헬스] Celltrion’s corona 19 treatment’Rekironaju’ approval is imminent… Opinion that approval is possible under the premise of Phase 3](https://cdn.bizwnews.com/news/thumbnail/202101/22949_23258_476_v150.jpg "[비즈헬스] Celltrion’s corona 19 treatment’Rekironaju’ approval is imminent… Opinion that approval is possible under the premise of Phase 3")
![[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓](https://image.ajunews.com/content/image/2021/01/13/20210113235100686144.jpg "[종합] Celltrion reduces the incidence of critically ill patients by 54% in phase 2 clinical trials of corona antibody treatment… Recovery period ↓")